What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
NuvaRing (Ethinyl Estradiol)
Prescription Required
You'll have option to make 4 interest-free payments by credit card once your order is confirmed using
-
Product Details
Description
NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) contains the hormones estrogen and progestin to prevent pregnancy in women.
Fact Table
Formula
C20H24O2
License
EU EMA
Bioavailability
38–48%
Legal status
Rx-Only
Chemical Name
Ethinylestradiol
Elimination half-life
7–36 hours
Dosage (Strength)
Ring
Pregnancy
-
Brands
NuvaRing
Protein binding
97–98%
PubChem CID
5991
MedlinePlus
a604032
ChEBI
4903
ATC code
G03CA01
DrugBank
DB00977
KEGG
D00554
Routes of administration
Vaginal (ring)
Directions
Follow the instructions that come with your NuvaRing prescription and read the information leaflets. If you have any concerns or questions about your prescription, reach out to your doctor or pharmacist.
NuvaRing is a vaginal ring made of a polymer. Each ring consists of 11.7 mg of etonogestrel and 2.7 mg of ethinyl estradiol, releasing approximately 0.12 mg of etonogestrel and 0.015 mg of ethinyl estradiol per day.
Choose a position that's comfortable for you. Squeeze the ring and insert it into the vagina. You may insert the ring using the applicator for NuvaRing instead. The ring should be kept in place for three weeks. At the beginning of the fourth week, remove the ring and leave it out for one week. After removal, place the ring in a foil pouch and dispose of it properly. Keep it away from children and pets. Do not flush the ring. Leave it out for one week. A new NuvaRing should be inserted one week after the last ring was removed, even if you are experiencing menstrual bleeding.
Ingredients
11.7 mg of etonogestrel and 2.7 mg of ethinyl estradiol is contained in each ring.
Contraindications
- If you are at risk for blood clotting conditions, you should not use NuvaRing. If you are older than 35 years old and smoke, currently have or have a history of a blood clot in the veins or lungs, have cerebrovascular disease, have coronary artery disease, have thrombogenic valvular or thrombogenic heart rhythm diseases, have inherited or acquired conditions in which your blood clots more than normal, have uncontrolled high blood pressure, have diabetes with vascular disease, have headaches with focal neurological symptoms, have migraines with aura, or if you have migraines and you are older than 35 years old, you may be at risk.
- If you have tumors of the liver, avoid using NuvaRing.
- If you have undiagnosed unusual vaginal bleeding, avoid using NuvaRing.
- Pregnant women should not use NuvaRing.
- If you have or have had breast cancer or other hormonally-sensitive cancers, do not use NuvaRing.
- Avoid using NuvaRing if you have any allergy to any ingredients in the ring.
- Avoid using NuvaRing if you suffer from Hepatitis C and take ombitasvir/paritaprevir/ritonavir with or without dasabuvir as this could cause an increase in ALT, a liver enzyme.
Cautions
WARNING: CIGARETTE SMOKING AND
SERIOUS CARDIOVASCULAR EVENTS
See full prescribing information for complete boxed warning.
- Women over 35 years old who smoke should not use NuvaRing.
- Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use.
- Before you begin using NuvaRing, tell your doctor:
- If you have any allergies
- About any medications you may take
- Certain medications and herbal supplements, including CYP3A4, may diminish NuvaRing's effectiveness or increase breakthrough bleeding. Back-up or a different form of birth control is recommended in patients who take these medications. Ask your doctor if you do not know whether or not you take these medications.
- If you have any health conditions
- About your pregnancy or breastfeeding status
- Vascular risks are associated with use of the NuvaRing; discontinue use if these occur. Stop using NuvaRing at least 4 weeks before and continue through 2 weeks after major surgery. Women may begin using NuvaRing 4 weeks after delivery if they are not breastfeeding.
- Use of NuvaRing may induce Toxic Shock Syndrome, requiring immediate treatment.
- Use of NuvaRing may cause liver problems; discontinue use if you develop yellowing of your skin or whites of your eyes.
- Use of NuvaRing may cause high blood pressure. Regularly monitor your blood pressure. Your doctor may discontinue use of NuvaRing if your blood pressure significantly increases.
- A decreased glucose tolerance may be caused by the use of NuvaRing. Changes in lipids may be experienced by women with the use of NuvaRing. A different form of birth control should be considered in women with uncontrolled dyslipidemia.
- Women with high levels of triglycerides or a family history of high levels of triglycerides may be at a higher risk of pancreatitis.
- NuvaRing use may cause or worsen gallbladder disease.
- Tell your doctor if you experience a significant change in headaches. Your doctor may discontinue NuvaRing usage.
- NuvaRing may induce unusual vaginal bleeding or you may stop having periods.
Side Effects
Some side effects associated with the use of NuvaRing are as follows: vaginal inflammation, headache, mood changes, depressed mood, expulsion, discomfort, or foreign body sensation, nausea, vomiting, vaginal discharge, weight gain, vaginal discomfort, breast pain, breast discomfort, breast tenderness, painful periods, stomach pain, acne, and decreased desire to have sex.
Reference:
NuvaRing (etonogestrel/ethinyl estradiol vaginal ring). Jersey City, NJ: Organon & Co.; 2022.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 9298
-
Product Reviews
